Assessment of Renal Toxicity Associated with Vancomycin in Patients with Health Care–Associated Methicillin-Resistant Staphylococcus Aureus Pneumonia: A Retrospective Analysis

Anand Kumar Singh¹*, Poonam Verma²

¹Associate Professor, ²Professor, Department of Physiology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, India

ABSTRACT

Background: One of the major causes of serious infections in both community and institutional settings is Staphylococcus aureus, with methicillin-resistant strains causing numerous invasive infections, especially those involving the bloodstream. Some practitioners have extrapolated these dosing recommendations with associated trough concentration goals to all vancomycin use. However, evidence of superior efficacy is lacking, and results of several single-centers, mostly retrospective trials have suggested that this more aggressive dosing may be related to an increased incidence of vancomycin-related nephrotoxicity and ototoxicity. Therefore, we retrospectively analyzed the rate of renal toxicity in patients treated with vancomycin for MRSA health care–associated pneumonia confirmed by bronchoalveolar lavage cultures.

Materials & Methods: The present study was carried out in the department of pharmacology and renal medicine and included all the patients with MRSA HCAP, microbiologically confirmed by BAL semiquantitative cultures, who were treated with vancomycin were eligible for this investigation. Patients with polymicrobial infection demonstrated by BAL cultures, those treated with vancomycin for <72 hours, and those with acute renal failure or requiring dialysis were excluded from evaluation. For all study patients, the following information was recorded by one of the investigators; age, sex, weight, serial serum creatinine (SCr) measurements, age- and sex-adjusted creatinine clearance (CrCl) and other parameters. Patients must have received the potentially renal toxic medication(s) while on vancomycin and before the maximum documented SCr (SCrmax) during treatment. Vasopressor use was considered when it was initiated or maintained within 48 hours before SCrmax. All the results were analyzed by SPSS software. Chi-square test was used for the assessment of level of significance.

Results: Mean age of the patients in group without and with renal toxicity was 58.2 and 61.2 years respectively. The mean male’s percentage in the patients of the group without renal toxicity and with renal toxicity was 58.2 and 69.2 respectively. 71.5 % and 81.7% were the mean percentage of whites in the group without and with renal toxicity. Mean APACHE II score in patients without and with renal toxicity was 18.6 and 23.1 respectively. Non-significant results were obtained while comparing the two study groups for the mean serum creatinine concentration and mean creatinine clearance. Significant correlation was obtained while comparing the vancomycin serum trough serum conc. (µg/mL) and percentage of renal toxicity.

Conclusion: Among patients treated for MRSA HCAP, aggressive vancomycin dosing and prolonged administration of vancomycin may be associated with renal toxicity.

Key Words: Renal, Staphylococcus, Vancomycin.

*Correspondence to:
Dr Anand Kumar Singh,
Associate Professor, Department of Physiology,
Shri Guru Ram Rai Institute of Medical and Health Sciences,
Dehradun, Uttarakhand, India.

Article History:
Received: 28-08-2016, Revised: 14-09-2016, Accepted: 26-09-2016
trials have suggested that this more aggressive dosing may be related to an increased incidence of vancomycin-related nephrotoxicity and ototoxicity.\textsuperscript{4,6} Therefore, we retrospectively analyzed the rate of renal toxicity in patients treated with vancomycin for MRSA health care-associated pneumonia (HCAP) confirmed by bronchoalveolar lavage (BAL) cultures.

**MATERIALS & METHODS**

The present study was carried out in the department of pharmacology and renal medicine and included all the patients with MRSA HCAP, microbiologically confirmed by BAL semiquantitative cultures, who were treated with vancomycin for MRSA HCAP who had received vancomycin and available through concentrations was generated by the Department of Medicine through retrospective query of the microbiology, laboratory, and pharmacy databases. For all study patients, the following information was recorded by one of the investigators (M.N.J.): age, sex, weight, serial serum creatinine (SCR) measurements, age- and sex-adjusted creatinine clearance (CrCl) calculated during receipt of vancomycin, measured vancomycin serum trough concentrations, duration of vancomycin therapy, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Patients must have received the potentially renal toxic medication(s) while on vancomycin and before the maximum documented SCR (SCrmax) during treatment. Vasopressor use was considered when it was initiated or maintained within 48 hours before SCrmax. All the results were analyzed by SPSS software. Chi-square test was used for the assessment of level of significance.

**RESULTS**

Graph 1 shows the demographic details of the patients in the two study groups. Mean age of the patients in group without and with renal toxicity was 58.2 and 61.2 years respectively. The mean male's percentage in the patients of the group without renal toxicity and with renal toxicity was 58.2 and 69.2 respectively. 71.5% and 81.7% were the mean percentage of whites in the group without and with renal toxicity. Mean APACHE II score in patients without and with renal toxicity was 18.6 and 23.1 respectively. Table 1 shows the p-value for the demographic details of the patients. Significant correlation was obtained while comparing the

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Without renal toxicity</th>
<th>With renal toxicity</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>58.2</td>
<td>61.2</td>
<td>0.415</td>
</tr>
<tr>
<td>Males (%)</td>
<td>58.2</td>
<td>69.2</td>
<td>0.652</td>
</tr>
<tr>
<td>White (%)</td>
<td>71.5</td>
<td>81.7</td>
<td>0.125</td>
</tr>
<tr>
<td>Mean APACHE II score</td>
<td>18.6</td>
<td>23.1</td>
<td>0.001*</td>
</tr>
<tr>
<td>Diabetic patients (%)</td>
<td>30.2</td>
<td>31.2</td>
<td>0.715</td>
</tr>
</tbody>
</table>

*: Significant, APACHE: Acute Physiology and Chronic Health Evaluation
mean APACHE II score in the patients of the two study groups. Graph 2 shows the baseline renal details of the patients. Table 2 shows the p-value for the baseline renal details of the patients. Non-significant results were obtained while comparing the two study groups for the mean serum creatinine concentration and mean creatinine clearance. Table 3 shows the occurrence of renal toxicity, stratified by vancomycin steady-state serum trough concentration. Significant correlation was obtained while comparing the vancomycin serum trough serum conc. (µg/mL) and percentage of renal toxicity.

Graph 2: Baseline renal details of the patients

Table 2: p-value for the baseline renal details of the patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Without renal toxicity</th>
<th>With renal toxicity</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean serum creatinine conc &gt; 1.4mg/dl (%)</td>
<td>19.2</td>
<td>15.6</td>
<td>0.777</td>
</tr>
<tr>
<td>Mean creatinine clearance mL/min</td>
<td>26.2</td>
<td>19.2</td>
<td>0.198</td>
</tr>
</tbody>
</table>

Table 3: Occurrence of renal toxicity, stratified by vancomycin steady-state serum trough concentration

<table>
<thead>
<tr>
<th>Vancomycin serum trough serum conc. (µg/mL)</th>
<th>Renal toxicity (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;15</td>
<td>28</td>
<td>0.001*</td>
</tr>
<tr>
<td>15-20</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>&gt;20</td>
<td>68</td>
<td></td>
</tr>
</tbody>
</table>

*: Significant

DISCUSSION
Vancomycin has been a mainstay of therapy for serious Staphylococcus aureus infections ever since its discovery in the 1950s. Although vancomycin was a second-line therapy early in its life cycle, it emerged as a first-line agent for infections due to MRSA in the 1970s. Over the next several decades, its usage dramatically increased due to the explosion of MRSA in both the community and health care settings. Despite the recent availability of alternative agents, vancomycin still remains the treatment of choice for serious MRSA infections. Despite its widespread use, there are growing concerns about the future role of vancomycin, particularly among patients who have invasive MRSA infections with vancomycin MICs of 1 mg/l liter. Although host- and pathogen-related factors have been implicated as a cause, suboptimal vancomycin dosing has been suggested as an alternative explanation for the poorer outcomes among these patients. Hence, we retrospectively analyzed the rate of renal toxicity in patients treated with vancomycin for MRSA health care–associated pneumonia (HCAP) confirmed by bronchoalveolar lavage (BAL) cultures.

In the present study, we observed that aggressive vancomycin dosing, as determined by maximum measured vancomycin serum trough concentrations ≥15 µg/mL, and prolonged vancomycin administration may be associated with renal toxicity among patients treated for MRSA HCAP. Jeffres et al investigated whether more aggressive vancomycin dosing is associated with greater risk for renal toxicity in patients with health care–associated pneumonia (HCAP) attributed to methicillin-resistant Staphylococcus aureus (MRSA). They retrospectively assessed the information about demographic, clinical and microbial details of the patients in a tertiary health care centre and observed that...
94 patients and concluded that aggressive vancomycin dosing and prolonged vancomycin administration may be associated with greater risk for renal toxicity in patients with MRSA HCAP.10 Hermsen et al evaluated the relationship of serum vancomycin trough concentration with clinical outcomes and nephrotoxicity for patients with deep-seated MRSA infection. They retrospectively analyzed adults with MRSA pneumonia, endocarditis or osteomyelitis who received vancomycin for > or = 5 days from June 2005 to June 2007. Patients were stratified by mean vancomycin trough level. Outcomes were clinical response, mortality, length of stay and nephrotoxicity. From the results, they concluded that clinical outcomes did not differ significantly between high and low trough groups for deep-seated MRSA infections. Nephrotoxicity was consistently higher in the high trough group, regardless of the definition used.11 Cano et al assessed the incidence of nephrotoxicity and associated risk factors in intensive care unit patients who received vancomycin for the treatment of HAP, VAP, and HCAP. They retrospectively analyzed data from a multicenter, observational study of pneumonia patients. Antibiotic-associated nephrotoxicity was defined as either an increase in serum creatinine ≥0.5 mg/dL or 50% above baseline, from initiation of vancomycin to 72 hours after completion of therapy. Univariate and multivariate logistic regression analyses were performed to identify risk factors for development of renal dysfunction. From the results, they concluded that Nephrotoxicity may be common among intensive care unit patients with pneumonia treated with broad-spectrum antibiotic therapy that includes vancomycin.12 Jeffres et al investigated whether vancomycin pharmacokinetic indexes (eg, serum trough concentrations or area under the concentration curve [AUC] values) were associated with mortality for patients with health-care-associated pneumonia (HCAP) attributed to methicillin-resistant Staphylococcus aureus (MRSA). They retrospectively analyzed adult patients requiring hospitalization who were identified as having HCAP attributed to MRSA by BAL semi-quantitative cultures. From the results, they concluded that no evidence was observed which could prove that greater vancomycin trough concentrations or AUC values correlated with hospital outcome.13

CONCLUSION
From the above results, the authors conclude that among patients treated for MRSA HCAP, aggressive vancomycin dosing and prolonged administration of vancomycin may be associated with renal toxicity.

REFERENCES

Source of Support: Nil. Conflict of Interest: None Declared.

Copyright: © the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882. This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.